American Society of Hematology

Figure 7

$Figure 7. Combination of b-AP15 with other anti-MM agents shows additive to synergistic effect in MM. (A) MM.1S cells were treated for 48 hours with b-AP15, SAHA, or b-AP15 plus SAHA and then assessed for viability by using the MTT assay. Isobologram analysis shows the synergistic cytotoxic effect of b-AP15 and SAHA. The graphs (right panel) are derived from the values given in the tables (left panel). CI <1 indicates synergy. (B) MM.1S cells were treated for 48 hours with b-AP15, lenalidomide, or b-AP15 plus lenalidomide and then assessed for viability by using an MTT assay. Synergistic anti-MM activity was analyzed as in panel (A). (C) MM.1S cells were treated for 48 hours with b-AP15, dexamethasone, or b-AP15 plus dexamethasone and then assessed for viability by using an MTT assay. Synergistic anti-MM activity was analyzed as in (A). Fa, fraction of viable cells.$

Combination of b-AP15 with other anti-MM agents shows additive to synergistic effect in MM. (A) MM.1S cells were treated for 48 hours with b-AP15, SAHA, or b-AP15 plus SAHA and then assessed for viability by using the MTT assay. Isobologram analysis shows the synergistic cytotoxic effect of b-AP15 and SAHA. The graphs (right panel) are derived from the values given in the tables (left panel). CI <1 indicates synergy. (B) MM.1S cells were treated for 48 hours with b-AP15, lenalidomide, or b-AP15 plus lenalidomide and then assessed for viability by using an MTT assay. Synergistic anti-MM activity was analyzed as in panel (A). (C) MM.1S cells were treated for 48 hours with b-AP15, dexamethasone, or b-AP15 plus dexamethasone and then assessed for viability by using an MTT assay. Synergistic anti-MM activity was analyzed as in (A). Fa, fraction of viable cells.

This Feature Is Available To Subscribers Only